Correction to: Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo efects of LenabasumTM

Correction to: Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo efects of Lenabasum^TM

Arthritis Res Ther. 2022 Mar 11;24(1):69. doi: 10.1186/s13075-022-02758-1.

Spandana Maddukuri^#^{1

2}, Jay Patel^#^{1

2}, De Anna Diaz^{1

2}, Kristen L Chen^{1

2}, Maria Wysocka², Christina Bax^{1

2}, Yubin Li^{1

2}, Adarsh Ravishankar^{1

2}, Madison Grinnell^{1

2}, Majid Zeidi³, Nithin Reddy⁴, Josef Symon S Concha^{1

2}, Muhammad M Bashir^{1

2}, Joyce Okawa^{1

2}, Barbara White⁵, Victoria P Werth^{6

7}

¹ Department of Dermatology, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA.
² Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
³ Department of Pathology, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.
⁴ Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.
⁵ Corbus Pharmaceuticals, Inc., Norwood, MA, USA.
⁶ Department of Dermatology, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA. werth@pennmedicine.upenn.edu.
⁷ Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. werth@pennmedicine.upenn.edu.

^# Contributed equally.

No abstract available